CLSD stock icon

Clearside Biomedical
CLSD

$1.15
2.68%
 

About: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Employees: 30

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 7 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

275% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 4

162% more capital invested

Capital invested by funds: $9.06M [Q4 2023] → $23.8M (+$14.7M) [Q1 2024]

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

8.37% more ownership

Funds ownership: 12.41% [Q4 2023] → 20.78% (+8.37%) [Q1 2024]

8% more funds holding

Funds holding: 48 [Q4 2023] → 52 (+4) [Q1 2024]

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
248%
upside
Avg. target
$4.57
298%
upside
High target
$6
422%
upside

7 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
335%upside
$5
Buy
Maintained
13 May 2024
Needham
Serge Belanger
248%upside
$4
Buy
Reiterated
13 May 2024
Needham
248%upside
$4
Buy
Reiterated
11 Apr 2024
HC Wainwright & Co.
Yi Chen
422%upside
$6
Buy
Reiterated
14 Mar 2024
JMP Securities
Jonathan Wolleben
335%upside
$5
Market Outperform
Reiterated
13 Mar 2024

Financial journalist opinion